BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23369103)

  • 1. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease.
    Matthes-Martin S; Lawitschka A; Fritsch G; Lion T; Grimm B; Breuer S; Boztug H; Karlhuber S; Holter W; Peters C; Minkov M
    Eur J Haematol; 2013 Apr; 90(4):308-12. PubMed ID: 23369103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience.
    Majumdar S; Robertson Z; Robinson A; Starnes S; Iyer R; Megason G
    Bone Marrow Transplant; 2010 May; 45(5):895-900. PubMed ID: 19784079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning.
    Mazur M; Kurtzberg J; Halperin E; Ciocci G; Szabolcs P
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):840-4. PubMed ID: 17164657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
    Krishnamurti L; Kharbanda S; Biernacki MA; Zhang W; Baker KS; Wagner JE; Wu CJ
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1270-8. PubMed ID: 18940682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation in SCD.
    Dalle JH
    C R Biol; 2013 Mar; 336(3):148-51. PubMed ID: 23643397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H
    Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases.
    Sawada A; Inoue M; Koyama-Sato M; Kondo O; Yamada K; Shimizu M; Isaka K; Kimoto T; Kikuchi H; Tokimasa S; Yasui M; Kawa K
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):214-21. PubMed ID: 24188918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease.
    Adamkiewicz TV; Mehta PS; Boyer MW; Kedar A; Olson TA; Olson E; Chiang KY; Maurer D; Mogul MJ; Wingard JR; Yeager AM
    Bone Marrow Transplant; 2004 Sep; 34(5):405-11. PubMed ID: 15247929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.
    Strullu M; Rialland F; Cahu X; Brissot E; Corradini N; Thomas C; Blin N; Rialland X; Méchinaud F; Mohty M
    Eur J Haematol; 2012 Jun; 88(6):504-9. PubMed ID: 22372430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
    Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients.
    Dedeken L; Lê PQ; Azzi N; Brachet C; Heijmans C; Huybrechts S; Devalck C; Rozen L; Ngalula M; Ferster A
    Br J Haematol; 2014 May; 165(3):402-8. PubMed ID: 24433465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
    Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
    Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.